Next-generation vaccines for infectious diseases

Next-generation vaccines are considered a promising approach to combating future disease outbreaks. Recent advancements in vaccine technologies have sped up the development of efficacious vaccines during the COVID-19 pandemic and are being tested for other pathogens. However, there remain many challenges for next-generation vaccines, which should target conserved epitopes, induce durable protection, and inhibit transmission of the disease-causing agent.

This cross-journal Collection welcomes submissions that propose technological advancements in vaccine/antigen design, target combinations, delivery systems for any pathogen groups, as well as adjunctive therapies. We encourage preclinical and clinical studies that evaluate vaccine safety and efficacy, including studies that test delivery routes, timing, and booster doses as part of the immunisation strategy. Moreover, epidemiological studies assessing or modeling coverage and effectiveness, with the aim to provide insight for further research, and guidance for policymakers, licensure, and regulatory framework will be considered.

This Collection is regularly updated with new content, selected by our editorial teams. Authors should refer to the aims and scope of Nature Communications, npj Vaccines, Communications Medicine, and Scientific Reports to determine the most appropriate journal for their manuscript. Submissions are welcome on a rolling basis.